A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 35
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : GEC
Long Form : gastroesophageal cancer
No. Year Title Co-occurring Abbreviation
2022 A narrative review of combining radiation and immunotherapy in gastroesophageal cancers. RT
2021 Brain metastases in gastroesophageal cancers-an underestimated complication. BrMs
2021 Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence. CPS, ICI
2021 Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. MMR/MSI, PD-1, PD-L1, TMB
2021 Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. OS, PS, PSM
2021 Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. CSCs, GC
2021 Volatile Organic Compounds in Human Exhaled Breath to Diagnose Gastrointestinal Cancer: A Meta-Analysis. AUC, CI, CRC, DOR, GIC, VOCs
2020 Histopathologic Response Is a Positive Predictor of Overall Survival in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany. HPR, NCT
2020 Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). GEJ, OS, PFS
10  2019 Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. CR, CT, SST, TTNTD
11  2018 Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials. CR, DCR, EGFR, ORR, OS, Peto OR, PFS, RCTs, TAs
12  2018 Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. ctDNA
13  2017 Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens. BC, CISH, DIA, HER2, IHC
14  2017 Novel Targeted Therapies for Esophagogastric Cancer. EGJ, GC
15  2017 Update on Gastroesophageal Adenocarcinoma Targeted Therapies. EGJ, GC
16  2016 Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. CapeOx, HR, OS, PFS, PPIs
17  2016 Evaluation of Response to Preoperative Chemotherapy Versus Surgery Alone in Gastroesophageal Cancer: Tumor Resectability, Pathologic Results and Post-Operative Complications. POC
18  2016 Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer. HRMs
19  2015 Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. CRC, OS, PFS, PK
20  2015 HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. GC, IHC
21  2015 Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. FISH, IHC, SRM-MS
22  2014 Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. FFPE, FISH, GCN, IHC, LOD, LT-SRM-MS
23  2014 HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. ---
24  2014 NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. FLOT, GEJ, NACT, pCR
25  2014 Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. ---
26  2013 Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. DWI, ICC, NT, TRG
27  2013 Concentration of serum interleukin-27 increase in patients with lymph node metastatic gastroesophageal cancer. IL-27, NCD
28  2013 Gastroesophageal cancer: focus on epidemiology, classification, and staging. AC, CT, EGJ, EUS, GC, PET, SCC
29  2013 Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. GC
30  2012 Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. pathCR, PET
31  2011 Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. NCI-CTCAE, OS, PFS, PS
32  2011 MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. ---
33  2011 [Proximal limits of resection and the role of mediastinal lymph dissection in surgical treatment of gastroesophageal cancer]. ---
34  2010 Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. DLT, RD, TEX
35  2009 Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. 5-FU